Nobivac NXT HCPChFeLV

Authorised

This medicine is authorised for use in the European Union

feline calicivirosis, feline rhinotracheitis, feline panleucopenia, feline chlamydiosis (live) and feline leukemia (self-amplifying RNA particle) vaccine

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

Product details

• Name of medicine:
  Nobivac NXT HCPChFeLV
• Active substance:
  • feline herpesvirus 1 (FHV), strain G2620A, live
  • feline calicivirus (FCV), strain F9, live
  • feline panleucopenia virus (FPL), strain MW-1
  • chlamydia felis, strain Baker, live
  • feline leukemia virus (FeLV) self-amplifying RNA (saRNA)-particle
• International non-proprietary name (INN) or common name:
  feline calicivirosis, feline rhinotracheitis, feline panleucopenia, feline chlamydiosis (live) and feline leukemia (self-amplifying RNA particle) vaccine

Pharmacotherapeutic group

• Immunologicals for felidae
• Other immunologicals

Authorisation details

• EMA product number:
  EMEA/V/C/006520

Assessment history

Initial marketing authorisation documents

CVMP summary of positive opinion for Nobivac NXT HCPChFeLV

Adopted Reference Number: EMA/CVMP/75635/2026 Rev. 1